|
JPS4875564A
(enExample)
|
1972-01-08 |
1973-10-11 |
|
|
|
JPS4988862A
(enExample)
|
1972-12-29 |
1974-08-24 |
|
|
|
US4883658A
(en)
|
1986-04-28 |
1989-11-28 |
Holly Frank J |
Ophthalmic solution for treatment of dry-eye syndrome
|
|
US4804539A
(en)
|
1986-07-28 |
1989-02-14 |
Liposome Technology, Inc. |
Ophthalmic liposomes
|
|
JPH0788376B2
(ja)
|
1986-09-02 |
1995-09-27 |
エーザイ株式会社 |
光学活性α−トコトリエノ−ルの製造方法
|
|
US5278151A
(en)
|
1987-04-02 |
1994-01-11 |
Ocular Research Of Boston, Inc. |
Dry eye treatment solution
|
|
US4914088A
(en)
|
1987-04-02 |
1990-04-03 |
Thomas Glonek |
Dry eye treatment solution and method
|
|
JP2685785B2
(ja)
|
1988-03-11 |
1997-12-03 |
エーザイ株式会社 |
光学活性α−トコトリエノールの製造方法
|
|
AU618791B2
(en)
|
1988-03-16 |
1992-01-09 |
Bioindustry Development Centre |
Production of high concentration tocopherols and tocotrienols from palm oil by-product
|
|
US5075104A
(en)
|
1989-03-31 |
1991-12-24 |
Alcon Laboratories, Inc. |
Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
|
|
US5157132A
(en)
|
1990-05-18 |
1992-10-20 |
Carotech Associates |
Integrated process for recovery of carotenoids and tocotrienols from oil
|
|
ZA912797B
(en)
|
1990-05-29 |
1992-12-30 |
Boston Ocular Res |
Dry eye treatment process and solution
|
|
ATE132366T1
(de)
|
1990-05-29 |
1996-01-15 |
Boston Ocular Res |
Zusammensetzung zur behandlung von dry eye erkrankungen
|
|
ZA927277B
(en)
|
1991-10-02 |
1993-05-19 |
Boston Ocular Res |
Dry eye treatment process and solution.
|
|
EP0543417A1
(en)
|
1991-11-22 |
1993-05-26 |
Lipogenics, Incorporated |
Tocotrienols and tocotrienol-like compounds and methods for their use
|
|
US5318993A
(en)
*
|
1993-04-16 |
1994-06-07 |
Bristol-Myers Squibb Company |
Antihyperlipidemic benzoquinones
|
|
AU684950B2
(en)
|
1994-05-06 |
1998-01-08 |
Alcon Laboratories, Inc. |
Use of vitamin E tocopheryl derivatives in ophthalmic compositions
|
|
HU226208B1
(en)
|
1994-12-28 |
2008-06-30 |
Janssen Pharmaceutica Nv |
Use of nebivolol for producing anti-atherogenic pharmaceuticals
|
|
US6232060B1
(en)
|
1996-01-19 |
2001-05-15 |
Galileo Laboratories, Inc. |
Assay system for anti-stress agents
|
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
|
EP1051412B1
(en)
|
1998-01-29 |
2003-09-24 |
Eastman Chemical Company |
Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof
|
|
WO2000078296A2
(en)
|
1999-06-17 |
2000-12-28 |
Basf Aktiengesellschaft |
Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
|
|
US6395915B1
(en)
|
1999-09-10 |
2002-05-28 |
Technikrom, Inc. |
Method for producing purified tocotrienols and tocopherols using liquid chromatography
|
|
US6528042B1
(en)
|
1999-10-08 |
2003-03-04 |
Galileo Laboratories, Inc. |
Compositions of flavonoids for use as cytoprotectants and methods of making and using them
|
|
US6426362B1
(en)
|
1999-10-08 |
2002-07-30 |
Galileo Laboratories, Inc. |
Formulations of tocopherols and methods of making and using them
|
|
MY127451A
(en)
|
1999-11-04 |
2006-12-29 |
Malaysian Palm Oil Board |
A method of chromatographic isolation for vitamin e isomers
|
|
DE10034233A1
(de)
|
2000-07-14 |
2002-01-24 |
Basf Ag |
Tocotrienolchinon-Cyclisierungsprodukte
|
|
GB0023555D0
(en)
*
|
2000-09-26 |
2000-11-08 |
Inst Of Ophthalmology |
Improvements in and relating to treatments for eye disease
|
|
US7034054B2
(en)
|
2000-12-15 |
2006-04-25 |
Galileo Pharmaceuticals, Inc. |
Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
|
|
US20020132845A1
(en)
|
2000-12-15 |
2002-09-19 |
Miller Guy Michael |
Compositions and methods for the prevention and treatment of tissue ischemia
|
|
US6838104B2
(en)
|
2000-12-20 |
2005-01-04 |
Archer Daniels Midland Company |
Process for the production of tocotrienols
|
|
US6608196B2
(en)
|
2001-05-03 |
2003-08-19 |
Galileo Pharmaceuticals, Inc. |
Process for solid supported synthesis of pyruvate-derived compounds
|
|
AU2002327517B2
(en)
|
2001-08-21 |
2008-04-17 |
Johnson & Johnson Consumer Companies, Inc. |
Tocopherol enriched compositions and amelioration of inflammatory symptoms
|
|
US20030144219A1
(en)
|
2001-11-15 |
2003-07-31 |
Phinney Stephen Dodge |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
|
US6653346B1
(en)
|
2002-02-07 |
2003-11-25 |
Galileo Pharmaceuticals, Inc. |
Cytoprotective benzofuran derivatives
|
|
US7078541B2
(en)
|
2002-02-07 |
2006-07-18 |
Galileo Pharmaceuticals, Inc. |
Benzofuran derivatives
|
|
DE60211875T2
(de)
|
2002-07-01 |
2006-10-26 |
Santhera Pharmaceuticals (Schweiz) Ag |
Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
|
|
JP4599292B2
(ja)
|
2002-10-30 |
2010-12-15 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
物理的−化学的特性に基づく治療用化合物の同定
|
|
US7015243B2
(en)
*
|
2003-08-28 |
2006-03-21 |
Allergan, Inc. |
Cyclohexyl prostaglandin analogs as EP4-receptor agonists
|
|
WO2005033092A1
(en)
|
2003-09-19 |
2005-04-14 |
Galileo Pharmaceuticals, Inc. |
Chroman derivatives
|
|
WO2005032478A2
(en)
*
|
2003-10-01 |
2005-04-14 |
Yasoo Health, Inc. |
Treatment for diabetic microvascular and macrovascular complications
|
|
WO2005035491A2
(en)
|
2003-10-10 |
2005-04-21 |
Yasoo Health, Inc. |
PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
|
|
WO2005090602A2
(en)
|
2004-03-18 |
2005-09-29 |
Sucampo Ag |
Method for diagnosing or predicting susceptibility to optic nueropathy
|
|
EP1611879B1
(en)
|
2004-07-02 |
2009-08-12 |
Novagali Pharma SA |
Use of emulsions for intra- and periocular injection
|
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
|
US20060241174A1
(en)
|
2005-04-22 |
2006-10-26 |
Anne Mueller |
Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use
|
|
EA035619B1
(ru)
|
2005-06-01 |
2020-07-16 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Композиции для использования в способе лечения митохондриальных нарушений
|
|
JP2009508867A
(ja)
|
2005-09-15 |
2009-03-05 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
|
|
JP5122460B2
(ja)
|
2005-09-16 |
2013-01-16 |
アラーガン、インコーポレイテッド |
治療薬の眼内輸送のための組成物および方法
|
|
EP1986636B1
(en)
*
|
2006-02-22 |
2013-04-24 |
Edison Pharmaceuticals, Inc. |
Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
|
|
WO2008086025A2
(en)
|
2007-01-10 |
2008-07-17 |
Edison Pharmaceuticals, Inc. |
Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
|
|
WO2008157747A1
(en)
|
2007-06-21 |
2008-12-24 |
The Jackson Laboratory |
Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
|
|
EP2170374A2
(en)
*
|
2007-07-03 |
2010-04-07 |
Andreas Reichert |
Method for treating diseases related to mitochondrial dysfunction
|
|
EP2187743B1
(en)
|
2007-08-16 |
2014-07-30 |
Santen Pharmaceutical Co., Ltd |
Rapamycin formulations for treatment of age related macular degeneration
|
|
US8075909B2
(en)
|
2007-09-04 |
2011-12-13 |
University Of Florida Research Foundation, Incorporated |
Contact lens based bioactive agent delivery system
|
|
PL2220030T3
(pl)
|
2007-11-06 |
2016-07-29 |
Bioelectron Tech Corp |
Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
|
|
WO2009088572A2
(en)
|
2008-01-07 |
2009-07-16 |
Centocor, Inc. |
Method of treating erythropoietin hyporesponsive anemias
|
|
EP2237664A4
(en)
|
2008-01-08 |
2013-05-22 |
Edison Pharmaceuticals Inc |
(HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
|
|
EP2262519A4
(en)
|
2008-03-05 |
2011-03-23 |
Edison Pharmaceuticals Inc |
TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
|
|
WO2009111576A2
(en)
|
2008-03-05 |
2009-09-11 |
Edison Pharmaceuticals, Inc. |
2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
|
|
EP2310038A4
(en)
|
2008-05-15 |
2012-03-14 |
Edison Pharmaceuticals Inc |
TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
|
|
WO2009143268A2
(en)
|
2008-05-22 |
2009-11-26 |
Edison Pharmaceuticals, Inc. |
Treatment of mitochondrial diseases with an erythropoietin mimetic
|
|
EP2303824B1
(en)
|
2008-06-25 |
2015-03-25 |
Edison Pharmaceuticals, Inc. |
2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
|
|
WO2010005989A1
(en)
|
2008-07-09 |
2010-01-14 |
Edison Pharmaceuticals, Inc. |
Dermatological compositions with anti-aging and skin even-toning properties
|
|
US20100029784A1
(en)
|
2008-07-30 |
2010-02-04 |
Hinman Andrew W |
Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
|
|
EP2344142B1
(en)
|
2008-09-10 |
2024-06-26 |
PTC Therapeutics, Inc. |
Treatment of pervasive developmental disorders with redox-active therapeutics
|
|
JP5731980B2
(ja)
|
2008-10-09 |
2015-06-10 |
ラムズコア， インコーポレイテッド |
ドライアイ症候群の処置のための組成物および方法
|
|
CA2740773A1
(en)
|
2008-10-14 |
2010-04-22 |
Edison Pharmaceuticals, Inc. |
Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
|
|
WO2010051277A1
(en)
|
2008-10-28 |
2010-05-06 |
Edison Pharmaceuticals, Inc. |
Process for the production of alpha-tocotrienol and derivatives
|
|
CA2777479C
(en)
|
2009-04-28 |
2017-10-17 |
Ptc Therapeutics, Inc. |
Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
|
|
WO2010126910A1
(en)
|
2009-04-28 |
2010-11-04 |
Edison Pharmaceuticals, Inc. |
Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
|
|
EA201101576A1
(ru)
|
2009-04-28 |
2012-04-30 |
Эдисон Фармасьютикалз, Инк. |
Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
|
|
JP2012531411A
(ja)
|
2009-06-25 |
2012-12-10 |
アンペア ライフ サイエンシーズ，インコーポレイテッド |
トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
|
|
NO2470168T3
(enExample)
|
2009-08-26 |
2018-06-30 |
|
|
|
WO2011041452A2
(en)
|
2009-10-01 |
2011-04-07 |
Ampere Life Sciences, Inc. |
Mouse model for identifying compounds for the treatment of oxidative stress
|
|
CA2797644A1
(en)
|
2009-12-31 |
2011-07-07 |
Edison Pharmaceuticals, Inc. |
Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
|
|
WO2011113018A1
(en)
|
2010-03-12 |
2011-09-15 |
Ampere Life Sciences, Inc. |
Measurement and control of biological time
|
|
EA201201374A1
(ru)
|
2010-04-06 |
2013-04-30 |
Эдисон Фармасьютикалз, Инк. |
Лечение атаксии-телеангиэктазии
|
|
AU2011245384C1
(en)
|
2010-04-27 |
2016-09-01 |
Bioelectron Technology Corporation |
Formulations of quinones for the treatment of ophthalmic diseases
|
|
WO2012009271A1
(en)
|
2010-07-14 |
2012-01-19 |
Penwest Pharmaceuticals Co. |
Methods of providing anticoagulation effects in subjects
|
|
US20130345312A1
(en)
|
2010-08-06 |
2013-12-26 |
Orion D. Jankowski |
Treatment of mitochondrial diseases with naphthoquinones
|
|
WO2012019032A1
(en)
|
2010-08-06 |
2012-02-09 |
Ampere Life Sciences, Inc. |
Treatment of mitochondrial diseases with vitamin k
|
|
WO2012068552A1
(en)
|
2010-11-19 |
2012-05-24 |
Edison Pharmaceuticals, Inc. |
Methods for improving blood glucose control
|
|
WO2012154613A1
(en)
|
2011-05-06 |
2012-11-15 |
Edison Pharmaceuticals, Inc. |
Improved process for the preparation of d-alpha-tocotrienol from natural extracts
|
|
WO2012170773A1
(en)
|
2011-06-08 |
2012-12-13 |
Edison Pharmaceuticals, Inc. |
Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
|
|
US9464016B2
(en)
|
2011-06-14 |
2016-10-11 |
Edison Pharmaceuticals, Inc. |
Catechol derivatives for treatment of oxidative stress diseases
|
|
ES2795798T3
(es)
|
2011-07-06 |
2020-11-24 |
Ptc Therapeutics Inc |
Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas
|
|
WO2013006736A1
(en)
|
2011-07-06 |
2013-01-10 |
Edison Pharmaceuticals, Inc |
Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
|
|
CA2842486C
(en)
|
2011-07-19 |
2022-09-06 |
Edison Pharmaceuticals, Inc. |
Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
|
|
CA2883879A1
(en)
|
2012-09-07 |
2014-03-13 |
Edison Pharmaceuticals, Inc. |
Quinone derivatives for use in the modulation of redox status of individuals
|
|
MX355430B
(es)
|
2013-03-08 |
2018-04-18 |
Unilever Nv |
Compuestos de resorcinol para uso dermatologico.
|
|
US9868711B2
(en)
|
2013-03-15 |
2018-01-16 |
Bioelectron Technology Corporation |
Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
|
|
US9670170B2
(en)
|
2013-03-15 |
2017-06-06 |
Bioelectron Technology Corporation |
Resorufin derivatives for treatment of oxidative stress disorders
|
|
US9296712B2
(en)
|
2013-03-15 |
2016-03-29 |
Edison Pharmaceuticals, Inc. |
Resorufin derivatives for treatment of oxidative stress disorders
|
|
JP2016515526A
(ja)
|
2013-03-15 |
2016-05-30 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
|
|
US20140275045A1
(en)
|
2013-03-15 |
2014-09-18 |
Edison Pharmaceuticals, Inc. |
Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
|
|
WO2014194292A1
(en)
|
2013-05-31 |
2014-12-04 |
Edison Pharmaceuticals, Inc. |
Carboxylic acid derivatives for treatment of oxidative stress disorders
|